Noodles & Company (NDLS) Drops 5.28% on January 01

Equities Staff  |

Noodles & Company (NDLS) was one of the Russell 2000's biggest losers for Friday January 01 as the stock slid 5.28% to $9.69, a loss of $-0.54 per share. Starting at an opening price of $10.06 a share, the stock traded between $9.67 and $10.23 over the course of the trading day. Volume was 300,753 shares over 1,837 trades, against an average daily volume of 197,564 shares and a total float of 27.71 million.

The losses send Noodles & Company down to a market cap of $268.49 million. In the last year, Noodles & Company has traded between $28.02 and $9.67, and its 50-day SMA is currently $11.43 and 200-day SMA is $14.31.

Noodles & Co is a fast casual restaurant concept offering lunch and dinner. Its menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads, sandwiches and appetizers served on china.

Noodles & Company is based out of Broomfield, CO and has some 9,500 employees. Its CEO is Kevin Reddy.

For a complete fundamental analysis analysis of Noodles & Company, check out’s Stock Valuation Analysis report for NDLS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.